Login to Your Account



Other News To Note


Tuesday, February 7, 2012
• Cytos Biotechnology Ltd., of Zurich, Switzerland, said its convertible bond restructuring has been approved, enabling the firm to remain a going concern while it continues searching for a sustainable strategic solution. The firm has had trouble tapping the public markets, despite reporting positive Phase II data with CYT003-QbG10 in allergic asthma and allergic rhinitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription